Modified iRGD exosomes demonstrated significant inhibition of CPT1A in tumor tissues and showed the ability to reverse oxaliplatin resistance and inhibit tumor growth by inhibiting fatty acid oxidation in vivo. This evidence concerns the gene CPT1A and neoplasm.